Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(3):249–264. doi: 10.1111/j.1527-3458.2001.tb00198.x

A Review of the Pharmacological and Clinical Profile of Mirtazapine

Sami A K Anttila 1,✉, Esa V J Leinonen 2
PMCID: PMC6494141  PMID: 11607047

ABSTRACT

The novel antidepressant mirtazapine has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic α2‐autoreceptors and α2‐heteroreceptors as well as by blocking 5‐HT2 and 5‐HT3 receptors. It enhances, therefore, the release of norepinephrine and 5‐HT1A‐mediated serotonergic transmission. This dual mode of action may conceivably be responsible for mirtazapine's rapid onset of action.

Mirtazapine is extensively metabolized in the liver. The cytochrome (CYP) P450 isoenzymes CYP1A2, CYP2D6, and CYP3A4 are mainly responsible for its metabolism. Using once daily dosing, steady‐state concentrations are reached after 4 days in adults and 6 days in the elderly. In vitro studies suggest that mirtazapine is unlikely to cause clinically significant drug‐drug interactions. Dry mouth, sedation, and increases in appetite and body weight are the most common adverse effects. In contrast to selective serotonin reuptake inhibitors (SSRIs), mirtazapine has no sexual side effects.

The antidepressant efficacy of mirtazapine was established in several placebo‐controlled trials. In major depression, its efficacy is comparable to that of amitriptyline, clomipramine, doxepin, fluoxetine, paroxetine, citalopram, or venlafaxine. Mirtazapine also appears to be useful in patients suffering from depression comorbid with anxiety symptoms and sleep disturbance. It seems to be safe and effective during long‐term use.

Keywords: Antidepressants, Clinical trials, Major depression, Mirtazapine

Full Text

The Full Text of this article is available as a PDF (145.4 KB).

References

  • 1. Abed RT, Cooper M. Mirtazapine causing hyperphagia. Br J Psychiatry 1999;174:181. [DOI] [PubMed] [Google Scholar]
  • 2. Abo‐Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazapine and clonidine. Pharmacotherapy 2000;20 (4): 476–478. [DOI] [PubMed] [Google Scholar]
  • 3. Anderson I, Tomenson B. The efficacy of selective serotonin re‐uptake inhibitors in depression: A meta‐analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238–249. [DOI] [PubMed] [Google Scholar]
  • 4. Benazzi F. Mirtazapine withdrawal symptoms. Can J Psychiatry 1998;43:525. [PubMed] [Google Scholar]
  • 5. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61 (9): 656–663. [DOI] [PubMed] [Google Scholar]
  • 6. Berger J, Ninan PT, Knight B, Selvig A, Nemeroff CB. Efficacy of mirtazapine in panic disorder [Abstract]. In: Scientific Abstracts of the 153rd Annual Meeting of the American Psychiatric Association (APA), May 1318, 2000. Chicago , IL .
  • 7. Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000;15 (6): 378–387. [DOI] [PubMed] [Google Scholar]
  • 8. Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RMA. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999;9:175–179. [DOI] [PubMed] [Google Scholar]
  • 9. Brannon GE, Rolland PD, Gary JM. Use of mirtazapine as prophylactic treatment for migraine headache. Psychosomatics 2000;41:153–154. [DOI] [PubMed] [Google Scholar]
  • 10. Bremner JD. A double‐blind comparison of Org 3770, amitriptyline and placebo in major depression. J Clin Psychiatry 1995;56:519–525. [PubMed] [Google Scholar]
  • 11. Bremner JD, Smith WT. Org 3770 vs amitriptyline in the continuation treatment of depression: A placebo controlled trial. Eur J Psychiatry 1996;10:5–15. [Google Scholar]
  • 12. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry 1998;59:233–235. [DOI] [PubMed] [Google Scholar]
  • 13. Bruijn JA, Moleman P, Mulder PGH. A double‐blind, fixed blood level study comparing mirtazapine with imipramine in depressed in‐patients. Psychopharmacology 1996;127:231–237. [PubMed] [Google Scholar]
  • 14. Bruijn JA, Moleman P, Mulder PGH, van den Broek WW. Comparison of 2 treatment strategies for depressed inpatients: Imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry 1998;59:657–663. [DOI] [PubMed] [Google Scholar]
  • 15. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60:45–49. [DOI] [PubMed] [Google Scholar]
  • 16. Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999;11:81–86. [DOI] [PubMed] [Google Scholar]
  • 17. Claghorn JL, Lesem MD. A double‐blind, placebo‐controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165–171. [DOI] [PubMed] [Google Scholar]
  • 18. Cohen M, Panagides J, Timmer CJ, Huisman JAM. Pharmacokinetics of mirtazapine from orally administered tablets: Influence of a high‐fat meal. Eur J Drug Metab Pharmacokinet 1997;22:103–110. [DOI] [PubMed] [Google Scholar]
  • 19. Connor KM, Davidson JRT, Weisler RH, Ahearn E. Apilot study of mirtazapine in post‐traumatic stress disorder. Int Clin Psychopharmacol 1999;14:29–31. [DOI] [PubMed] [Google Scholar]
  • 20. Dahl M‐L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997;13:37–46. [Google Scholar]
  • 21. Davis R, Wilde M. Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996;5:389–402. [DOI] [PubMed] [Google Scholar]
  • 22. Davis JM, Giakas WJ. Mirtazapine: The first million patients [Abstract]. In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology, December 1418, 1998. Las Croabas, Puerto Rico : 304. [Google Scholar]
  • 23. De Boer T. The pharmacological profile of mirtazapine. J Clin Psychiatry 1996;57 (Suppl 4): 19–25. [PubMed] [Google Scholar]
  • 24. Debonnel G, Gobbi G, Turcotte J, et al. Effects of mirtazapine, paroxetine and their combination: A double‐blind study in major depression [Abstract]. Eur Neuropsychopharmacol 2000;10(Suppl 3): S252. [Google Scholar]
  • 25. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 1998;15:45–55. [DOI] [PubMed] [Google Scholar]
  • 26. Dodd S, Boulton DW, Burrows GD, DeVane CL, Norman TR. Metabolism of enantiomers of mirtazapine by recombinant human cytochrome P450 enzymes and human liver microsomes [Abstract]. Int J Neuropsychopharmacol 2000;3(Suppl 1): S213. [Google Scholar]
  • 27. Dunner DL, Hendrickson HE, Budech C, et al. Mirtazapine: Treatment of dysthymic disorder In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology, December 1418, 1998. Las Croabas, Puerto Rico . [Google Scholar]
  • 28. Ebes F, Van Lookeren‐Campagne AM, Hartmans HLA, et al. A phase I, single‐center, single‐blind, placebo‐controlled multiple dose study of the interaction between Org 3770 and carbamazepine in healthy male volunteers (Study 22514, Report No. NL0003854). Oss : N. V. Organon, 1998. Data on file. [Google Scholar]
  • 29. Elliot AJ, Roy‐Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000;20:265–267. [DOI] [PubMed] [Google Scholar]
  • 30. Falkai P. Mirtazapine: Other indications. J Clin Psychiatry 1999;60 (Suppl 17): 36–40. [PubMed] [Google Scholar]
  • 31. Farah A. Lack of sexual adverse effects with mirtazapine [letter]. Am J Health System Pharm 1998;55:2195–2196. [DOI] [PubMed] [Google Scholar]
  • 32. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000:61 (Suppl 11): 37–41. [PubMed] [Google Scholar]
  • 33. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disorders 1998;51:267–285. [DOI] [PubMed] [Google Scholar]
  • 34. Fawcett J, Barkin RL. A meta‐analysis of eight randomized, double‐blind controlled trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59:123–127. [PubMed] [Google Scholar]
  • 35. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI‐induced sexual dysfunction. Biol Psychiatry 1998;15(43 Suppl): 104S. [DOI] [PubMed] [Google Scholar]
  • 36. Goodnick PJ, Kremer C, Wingard P. Weight change during mirtazapine therapy. Prim Psychiatry 1998;3:103–108. [Google Scholar]
  • 37. Goodnick PJ, Puig A, DeVane CL, Freund BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999;60:446–448. [DOI] [PubMed] [Google Scholar]
  • 38. Guelfi J‐D, Ansseau M, Timmerman L, et al. Efficacy and tolerability of mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholia. Poster presented at the 38th Annual Meeting of the American College of Neuropsychopharmacology, December 1216, 1999. Acapulco, Mexico . [Google Scholar]
  • 39. Guest J, Brown MCJ, Nimmerrichter AA. Economic impact of using mirtazapine in the management of moderate and severe depression in Austria [Abstract PM04009]. In: The XXIth Collegium Internationale Neuro‐Psychopharmacologiucum (CINP) Congress , July 1216, 1998. Glasgow , United Kingdom .
  • 40. Halikas JA. Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10:125–133. [Google Scholar]
  • 41. Hesselmann B, Habeler A, Praschak‐Rieder N, et al. Mirtazapine in seasonal affective disorder (SAD): A preliminary report. Hum Psychopharmacol Clin Exp 1999;14:59–62. [Google Scholar]
  • 42. Holm KJ, Markhan A. Mirtazapine. A review of its use in major depression. Drugs 1999;57 (4): 607–631. [DOI] [PubMed] [Google Scholar]
  • 43. Høyberg OJ, Maragakis B, Mullin J, et al. A double‐blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996;93:184–190. [DOI] [PubMed] [Google Scholar]
  • 44. Ichim C, Berk M, Brook S. Mirtazapine treatment of negative symptoms of schizophrenia: A double blind placebo controlled add on trial to treatment with haloperidol [Abstract]. Int J Neuropsychopharmacol 2000;3(Suppl1): S112. [Google Scholar]
  • 45. Isaac MT, Tome MB. Mirtazapine in peri‐menopausal depression: An open label study. In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology , December 1418, 1998. Las Croabas , Puerto Rico .
  • 46. Jefferson JW. Drug interactions‐friend or foe J Clin Psychiatry 1998;59 (Suppl 4): 37–47. [PubMed] [Google Scholar]
  • 47. Joffe H, Groninger HL, Soares CN, Cohen LS. An open trial of mirtazapine in menopausal women with depression refractory to estrogen‐replacement therapy [Abstract]. In: Scientific Abstracts of the 153rd Annual Meeting of the American Psychiatric Association (APA) , May 1318, 2000. Chicago , IL .
  • 48. Kapezinski F, Ribeiro L, Busnello JV, et al. Mirtazapine versus fluoxetine in panic disorder [Abstract]. In: Scientific Abstracts of the 153rd Annual Meeting of the American Psychiatric Association (APA) , May 1318, 2000. Chicago , IL .
  • 49. Kasper S. Clinical efficacy of mirtazapine: A review of meta‐analyses of pooled data. Int Clin Psychopharmacol 1995;10:25–35. [DOI] [PubMed] [Google Scholar]
  • 50. Kasper S, Praschak‐Riedel N, Tauscher J, et al. A risk‐benefit assessment of mirtazapine in the treatment of depression. Drug Safety 1997;17:251–264. [DOI] [PubMed] [Google Scholar]
  • 51. Keller MB. Long‐term management of depression. In: Keller MB, Pinder RM, chairs. The role of mirtazapine in the pharmacotherapy of depression (Academic Highlights). J Clin Psychiatry 2000;61:614. [Google Scholar]
  • 52. Kent JM. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet 2000;355:911–918. [DOI] [PubMed] [Google Scholar]
  • 53. Khan MC. A randomized, double‐blind, placebo‐controlled 5‐weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995;10:119–124. [Google Scholar]
  • 54. Klesmer J, Sarcevic A, Fomari V. Panic attacks during discontinuation of mirtazapine. Can J Psychiatry 2000;45 (6): 570–571. [PubMed] [Google Scholar]
  • 55. Koran L, Quirk T, Lorberbaum J. Mirtazapine treatment of obsessive‐compulsive disorder. Eur Neuropsychopharmacology 1999;9(Suppl 5): S305. [DOI] [PubMed] [Google Scholar]
  • 56. Kraus T, Haack M, Schuld A, Pollmächer T. Weight gain during treatment with mirtazapine goes along with an increase in plasma levels of cytokines and leptin [Abstract]. Eur Neuropsychopharmacol 2000;10(Suppl 3): S272. [Google Scholar]
  • 57. Laakmann G, Schüle C, Baghai T, Waldvogel E. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999;24:769–784. [DOI] [PubMed] [Google Scholar]
  • 58. Laakmann G, Schüle C, Baghai T, Waldvogel E, Bidlingmaier M, Strasburger C. Mirtazapine: An inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000;20:101–103. [DOI] [PubMed] [Google Scholar]
  • 59. Lahdelma L, Zivkov M. The clinical course and resolution of mirtazapine‐induced edema. [Abstract PM02110]. In: The XXIth Collegium Internationale Neuro‐Psychopharmacologicum (CINP) Congress , July 1216, 1998. Glasgow , United Kingdom .
  • 60. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: A double‐blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999;14:329–337. [DOI] [PubMed] [Google Scholar]
  • 61. Loonen AJM, Doorschot CH, Oostelbos MCJM, Sitsen JMA. Lack of interactions between mirtazapine and risperidone in psychiatric patients: A pilot study. Eur Neuropsychopharmacol 1999;10:51–57. [DOI] [PubMed] [Google Scholar]
  • 62. Mattila M, Mattila MJ, Vrijmoed‐de Vries M, et al. Actions and interactions of psychotropic drugs on human performance and mood: Single doses of Org 3770, amitriptyline and diazepam (Study 85148, Report No. 2468). Oss : N. V. Organon, 1989. Data on file. [DOI] [PubMed] [Google Scholar]
  • 63. Marttila M, Jääskeläinen J, Järvi R, et al. A double‐blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995;5:441–446. [DOI] [PubMed] [Google Scholar]
  • 64. Mercer AJ. The effects of ethanol alone and its interactions with other compounds on the dynamics of the saccadic eye movement system [thesis]. Cardiff : Department of Medicine, University of Wales, 1992:202–255. [Google Scholar]
  • 65. Mink L, Heftink N, Jonkman JGH, et al. Pharmacokinetics of mirtazapine in combination with amitriptyline. In: 11th European College of Neuropsychopharmacology Congress , 1998. Paris , France , 1.039.
  • 66. Montgomery SA. Safety of mirtazapine: Areview. Int Clin Psychopharmacol 1995;10 (Suppl 4): 37–45. [DOI] [PubMed] [Google Scholar]
  • 67. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long‐term treatment of depression: A double‐blind, placebo‐controlled study. Int Clin Psychopharmacol 1998;18:63–73. [DOI] [PubMed] [Google Scholar]
  • 68. Mullin J, Lodge A, Bennie E, et al. A multicentre, double‐blind, amitriptyline‐controlled study of mirtazapine in patients with major depression. J Psychopharmacol 1996;10:235–240. [DOI] [PubMed] [Google Scholar]
  • 69. Pact V, Gidus T. Mirtazapine treats resting tremor, essential tremor, and levodopa‐induced dyskinesias. Neurology 1999;53:1154. [DOI] [PubMed] [Google Scholar]
  • 70. Posey DJ, Guenin KD, Kohburn A, Swiezy NB, McDougle CJ. A systematic open‐label trial of mirtazapine in autism and related pervasive developmental disorders [Abstract]. In: Scientific Abstracts of the 153rd Annual Meeting of the American Psychiatric Association (APA) , May 1318, 2000. Chicago , IL .
  • 71. Preskorn SH, Omo K, Magnus R, et al. Immediate crossover from fluoxetine to mirtazapine. Biol Psychiatry 1997;41:96S. [Google Scholar]
  • 72. Radhakishun FS, van Den Bos, van Der Heijden, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychophamacol 2000;20:531–537. [DOI] [PubMed] [Google Scholar]
  • 73. Ramaekers JG, Muntjewerff ND, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 1998;13 (Suppl 2): S87–S97. [Google Scholar]
  • 74. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double‐blind, clomipramine controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263–271. [Google Scholar]
  • 75. Roose SP. The tolerability and safety of antidepressants. In: Keller MB, Pinder RM, chairs. The role of mirtazapine in the pharmacotherapy of depression (Academic Highlights). J Clin Psychiatry 2000;61:609–616. [DOI] [PubMed] [Google Scholar]
  • 76. Simhandi C, Zhoglami A, Pinder R. Pregnancy during use of mirtazapine [Abstract]. 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress , July 1216, 1998. Glasgow , United Kingdom .
  • 77. Sitsen JMA, Zivkov M. Mirtazapine: Clinical profile. CNS Drugs 1995;4 (Suppl 1): 39–48. [Google Scholar]
  • 78. Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 2000;14 (2): 172–176. [DOI] [PubMed] [Google Scholar]
  • 79. Sitsen JMA, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: A drug‐drug interaction study in healthy male subjects. Eur J Clin Pharmacol 2000;56:389–394. [DOI] [PubMed] [Google Scholar]
  • 80. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990:26:191–196. [PubMed] [Google Scholar]
  • 81. Soutullo CA, McElroy SL, Keck PE. Hypomania associated with mirtazapine augmentation of sertraline. J Clin Psychiatry 1998:59:320. [DOI] [PubMed] [Google Scholar]
  • 82. Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W. Meta‐analysis of randomized, double‐blind, placebo‐controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand 1997;391 (Suppl): 22–30. [DOI] [PubMed] [Google Scholar]
  • 83. Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P‐450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000;28:1168–1175. [PubMed] [Google Scholar]
  • 84. Söderström B. Mirtazapine and ECT as combination therapy [Abstract]. Eur Neuropsychopharmacol 1999;9(Suppl5): S229. [Google Scholar]
  • 85. Sørensen M, Jørgensen J, Viby‐Mogensen J, Bettum V, Dunbar GC, Steffensen K. A double‐blind group comparative study using the new antidepressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985;71:339–346. [DOI] [PubMed] [Google Scholar]
  • 86. Tanum L, Moe N. Mirtazapine in the treatment of irritable bowel syndrome: A pilot study [Abstract]. Eur Neuropsychopharmacol 1999;9(Suppl 5): S365. [Google Scholar]
  • 87. Thomas SG. Irritable bowel syndrome and mirtazapine. Am J Psychiatry 2000;157:1341–1342. [DOI] [PubMed] [Google Scholar]
  • 88. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60 (Suppl 17): 18–22. [PubMed] [Google Scholar]
  • 89. Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000;41:356–359. [DOI] [PubMed] [Google Scholar]
  • 90. Timmer JC, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000;38:461–474. [DOI] [PubMed] [Google Scholar]
  • 91. Turan M, Askin R, Telcioglu M, Çilli AS. Mirtazapine versus amitriptyline in treatment of major depressive disorder [Abstract]. Eur Neuropsychopharmacol 2000;10(Suppl 3): S228. [Google Scholar]
  • 92. Van Hensbeek I, Lahdelma L, Martikainen Y. Treatment of bulimia nervosa and binge‐eating with mirtazapine [Abstract]. Int J Neuropsychopharmacol 2000;3(Suppl 1): S299. [Google Scholar]
  • 93. Van Lookeren‐Campagne AM, Hartmans HLA, Ruwe FJL, et al. A phase I, single center, randomized, partially double‐blind, multiple dose, three‐way cross‐over study of the pharmacokinetic and pharmacodyna‐mic interaction of Org 3770 (mirtazapine) and paroxetine in healthy volunteers (Study 22511, Report No. NL 0010166). Oss: N. V Organon , 1998. Data on file. [Google Scholar]
  • 94. Van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: A double‐blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; . [PubMed] [Google Scholar]
  • 95. Van Vliet IM, van Veen F, Westenberg HGM. Mirtazapine in social anxiety disorder [Abstract]. Int J Neuropsychophamacol 2000;3(Suppl 3): S283. [Google Scholar]
  • 96. Vartiainen H, Leinonen E. Double‐blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4:145–150. [DOI] [PubMed] [Google Scholar]
  • 97. Vester‐Blokland E, Den Boer J, Boshuizen M, et al. Mirtazapine in patients with panic disorder [Abstract]. Int J Neuropsychopharmacol 2000;3(Suppl 1): S227. [Google Scholar]
  • 98. Waldinger MD, Berendsen HH, Schweitzer DH. Treatment of hot flushes with mirtazapine: Four case reports. Maturitas 2000;36 (3): 165–168. [DOI] [PubMed] [Google Scholar]
  • 99. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306–312. [PubMed] [Google Scholar]
  • 100. Wittgens W, Trenckman U, Donath O. Mirtazapine in elderly inpatients with somatic or neurological comorbidity. Poster presented at the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress, July 12–16, Glasgow , United Kingdom .
  • 101. Zedkova L, Coupland NJ. Hypertension during coprescription of mirtazapine and low‐dose amitriptyline. Can J Psychiatry 1998;43:858–859. [PubMed] [Google Scholar]
  • 102. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: A 6‐week randomized double‐blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173–180. [Google Scholar]
  • 103. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs. amitriptyline inpatients with major depressive disorder: A meta‐analysis. Hum Psychopharmacol 1995:S135–S145. [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES